Our results, therefore, indicate that CXCL13 neutralizing MAb 5261 antibody has potential for treatment of autoimmune disorders, including Multiple Sclerosis and Rheumatoid Arthritis. The gene discussed is CXCL13; the disease is autoimmune disease.